---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-049048"
form_type: "8-K"
ticker: "XAIR"
cik: "0001641631"
company_name: "Beyond Air, Inc."
filed_at: "2024-12-06T23:59:59+00:00"
generated_at: "2026-05-29T06:37:14.721721+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Beyond Cancer (Beyond Air) gets Israeli MoH approval for Phase 1b LV UNO + anti-PD-1 trial for solid tumors

## Summary
- Israeli Ministry of Health approved Phase 1b trial of LV UNO in combination with anti-PD-1 therapy for solid tumors.
- Trial will enroll up to 20 patients with unresectable solid tumors that progressed or were stable on PD-1 inhibitors.
- Primary endpoint: objective response rate (ORR) and duration of response per RECIST v1.1; secondary immune-related response.
- Four Israeli sites; patient screening Q1 2025; topline data expected second half of 2025.
- Preclinical data showed single UNO dose increased PD-L1 expression and improved survival vs anti-PD-1 alone.

## SEC filing metadata
- accession: 0001493152-24-049048
- form_type: 8-K
- ticker: XAIR
- cik: 0001641631
- company_name: Beyond Air, Inc.
- filed_at: 2024-12-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641631/000149315224049048/0001493152-24-049048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641631/000149315224049048/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-049048
- JSON: https://secwatch.observer/filing/0001493152-24-049048.json
- Plain text: https://secwatch.observer/filing/0001493152-24-049048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.